In combination therapy, for GDF6-high-expressing tumors, the combination of MDSC inhibitors (such as SX-682) [41] or PARP inhibitors (in HRD-positive cancer types) [42] may reverse immune suppression. This evidence concerns the gene GDF6 and cancer.